公开(公告)号：US20250066388A1

公开(公告)日：2025-02-27

申请号：US18595898

申请日：2024-03-05

Applicant: AbbVie Inc.

Inventor： George A. Doherty ,  Vikram Bhat ,  Andrew S. Judd ,  Andrew J. Souers ,  Patrick Brady ,  Yujia Dai ,  Jianchun Gong ,  Yiyun Yu

IPC: C07D519/00

Abstract: The present invention provides for compounds of Formula (I) wherein A, L, W, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL, SLL, and/or ALL.

公开(公告)号：US20230399340A1

公开(公告)日：2023-12-14

申请号：US18046011

申请日：2022-10-12

Applicant: AbbVie Inc. ,  AbbVie Deutschland GmbH & Co. KG

Inventor： Wilfried Braje ,  George Doherty ,  Katja Jantos ,  Cheng Ji ,  Andrew Judd ,  Aaron Kunzer ,  Anthony Mastracchio ,  Xiaohong Song ,  Andrew Souers ,  Gerard Sullivan ,  Zhi-Fu Tao ,  Chunqiu Lai ,  Andreas Kling ,  Frauke Pohlki ,  Jesse Teske ,  Michael Wendt ,  Patrick Brady ,  Xilu Wang ,  Thomas Penning ,  Michael Michaelides

IPC: C07D495/16 ,  A61P35/00 ,  C07D519/00

CPC classification number: C07D495/16 ,  A61P35/00 ,  C07D519/00

Abstract: The present disclosure provides for compounds of Formula (I)




wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

公开(公告)号：US20220259226A1

公开(公告)日：2022-08-18

申请号：US17660355

申请日：2022-04-22

Applicant: AbbVie Inc. ,  AbbVie Deutschland GmbH & Co. KG

Inventor： Wilfried Braje ,  George Doherty ,  Katja Jantos ,  Cheng Ji ,  Andrew Judd ,  Aaron Kunzer ,  Anthony Mastracchio ,  Xiaohong Song ,  Andrew Souers ,  Gerard Sullivan ,  Zhi-Fu Tao ,  Chunqiu Lai ,  Jesse Teske ,  Michael Wendt ,  Patrick Brady ,  Xilu Wang ,  Thomas Penning ,  Yujia Dai ,  Jane Gong ,  Roberto Risi ,  Yiyun Yu ,  Guidong Zhu

IPC: C07D498/18 ,  A61P35/00 ,  C07D519/00 ,  C07D495/18 ,  C07D495/16 ,  A61K31/519 ,  C07D491/16 ,  C07D498/16

Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

公开(公告)号：US20240228509A1

公开(公告)日：2024-07-11

申请号：US18365044

申请日：2023-08-03

Applicant: AbbVie Inc. ,  AbbVie Deutschland GmbH & Co. KG

Inventor： Wilfried Braje ,  George Doherty ,  Katja Jantos ,  Cheng Ji ,  Andrew Judd ,  Aaron Kunzer ,  Anthony Mastracchio ,  Xiaohong Song ,  Andrew Souers ,  Gerard Sullivan ,  Zhi-Fu Tao ,  Chunqiu Lai ,  Andreas Kling ,  Frauke Pohlki ,  Jessee Teske ,  Michael Wendt ,  Patrick Brady ,  Xilu Wang ,  Thomas Penning ,  Michael Michaelides

IPC: C07D495/16 ,  A61P35/00 ,  C07D519/00

CPC classification number: C07D495/16 ,  A61P35/00 ,  C07D519/00

Abstract: The present disclosure provides for compounds of Formula (I)






wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

公开(公告)号：US20230234971A1

公开(公告)日：2023-07-27

申请号：US18156987

申请日：2023-01-19

Applicant: AbbVie Inc.

Inventor： George A. Doherty ,  Vikram Bhat ,  Patrick Brady ,  Yujia Dai ,  Jianchun Gong ,  Andrew S. Judd ,  Andrew J. Souers ,  Yiyun Yu

IPC: C07D519/00

CPC classification number: C07D519/00

Abstract: The present invention provides for compounds of Formula (I)




wherein A, L, W, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL, SLL, and/or ALL.